2019
PD66-04 NATIONAL TRENDS AND PATHOLOGIC OUTCOMES OF NEOADJUVANT CHEMOTHERAPY AMONG PATIENTS WITH MICROPAPILLARY VARIANT UROTHELIAL CARCINOMA OF THE BLADDER
Javier-DesLoges* J, Abello A, Syed J, Sprenkle P, Hurwitz M, Kenney P, Leapman M. PD66-04 NATIONAL TRENDS AND PATHOLOGIC OUTCOMES OF NEOADJUVANT CHEMOTHERAPY AMONG PATIENTS WITH MICROPAPILLARY VARIANT UROTHELIAL CARCINOMA OF THE BLADDER. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000557466.16539.88.Peer-Reviewed Original Research
2017
PD04-09 SHOULD PATIENTS WITH METASTATIC NON-CLEAR CELL RENAL CELL CARCINOMA UNDERGO CYTOREDUCTIVE NEPHRECTOMY?
Keskin S, Petros F, Yu K, Aboshady Y, Borregales L, Kenney P, Matin S, Karam J, Wood C. PD04-09 SHOULD PATIENTS WITH METASTATIC NON-CLEAR CELL RENAL CELL CARCINOMA UNDERGO CYTOREDUCTIVE NEPHRECTOMY? Journal Of Urology 2017, 197: e65-e66. DOI: 10.1016/j.juro.2017.02.228.Peer-Reviewed Original Research
2014
1042 Predictors of occult lymph node metastases in patients with locally advanced renal cell carcinoma: Who should have a lymph node dissection?
Babaian K, Kenney P, Karam J, Wood C. 1042 Predictors of occult lymph node metastases in patients with locally advanced renal cell carcinoma: Who should have a lymph node dissection? European Urology Open Science 2014, 13: e1042. DOI: 10.1016/s1569-9056(14)61024-1.Peer-Reviewed Original ResearchMP64-03 PREDICTORS OF OCCULT LYMPH NODE METASTASES IN PATIENTS WITH RENAL CELL CARCINOMA: WHO SHOULD UNDERGO A LYMPH NODE DISSECTION?
Babaian K, Kenney P, Kim D, Qiao W, Karam J, Wood C. MP64-03 PREDICTORS OF OCCULT LYMPH NODE METASTASES IN PATIENTS WITH RENAL CELL CARCINOMA: WHO SHOULD UNDERGO A LYMPH NODE DISSECTION? Journal Of Urology 2014, 191: e701. DOI: 10.1016/j.juro.2014.02.1920.Peer-Reviewed Original Research
2012
Re: Comparative Effectiveness of Axitinib Versus Sorafenib in Advanced Renal Cell Carcinoma (AXIS): A Randomised Phase 3 Trial
Kenney PA, Wood CG. Re: Comparative Effectiveness of Axitinib Versus Sorafenib in Advanced Renal Cell Carcinoma (AXIS): A Randomised Phase 3 Trial. European Urology 2012, 62: 182-183. PMID: 22640859, DOI: 10.1016/j.eururo.2012.04.013.Peer-Reviewed Original ResearchIntegration of Surgery and Systemic Therapy for Renal Cell Carcinoma
Kenney PA, Wood CG. Integration of Surgery and Systemic Therapy for Renal Cell Carcinoma. Urologic Clinics Of North America 2012, 39: 211-231. PMID: 22487764, DOI: 10.1016/j.ucl.2012.01.005.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, HormonalCarcinoma, Renal CellChemotherapy, AdjuvantCombined Modality TherapyFemaleHumansImmunotherapyKidney NeoplasmsMaleNeoadjuvant TherapyNeoplasm InvasivenessNeoplasm StagingNephrectomyPrognosisRadiotherapy, AdjuvantRisk AssessmentSurvival AnalysisTreatment OutcomeConceptsRenal cell carcinomaSystemic therapyCell carcinomaMetastatic renal cell carcinomaAdvanced nonmetastatic diseaseUpfront cytoreductive nephrectomyIntegration of surgeryCytoreductive nephrectomyCytoreductive surgeryNeoadjuvant therapyNonmetastatic diseaseAdjuvant therapyMetastatic diseaseAppropriate patientsTherapySurgeryDiseaseCurrent roleNephrectomyFurther studiesCarcinomaPotential benefitsPatientsTrials